2026年6月最新影响因子数据已更新，欢迎查询使用。如果您对期刊系统有任何需求或者问题，欢迎反馈给我们。
 |
体验更多LetPub AI科研工具 >> | |
| 近期推荐： | 热 全流程投稿协助套餐服务 | 热 SCI论文AI润色+人工QC服务 | 热 Springer Nature特刊征稿 | 新 已发表SCI？是时候来Springer出书了！ |
 |
| 基本信息 | 登录收藏 | |||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
期刊名字 | Journal for ImmunoTherapy of Cancer J IMMUNOTHER CANCER （此期刊被最新的JCR期刊SCIE收录） LetPub评分 8.5
66人评分
我要评分
声誉 9.2 影响力 8.0 速度 7.0 | |||||||||||||||||||||||||||||||||||||
| 期刊ISSN | 2051-1426 | 安装APP，查看期刊最新消息
| ||||||||||||||||||||||||||||||||||||
| 2025-2026最新IF （数据来源于网友提供） | 注册或登录后，查看IF | |||||||||||||||||||||||||||||||||||||
| 实时影响因子 | 截止2026年5月06日：10.95 | |||||||||||||||||||||||||||||||||||||
| 2025-2026自引率 | 3.4%点击查看自引率趋势图 | |||||||||||||||||||||||||||||||||||||
| 五年IF （数据来源于网友提供） | 12.297数据由网友[憧憬奶茶]收集提供 | |||||||||||||||||||||||||||||||||||||
| h-index | 36 | |||||||||||||||||||||||||||||||||||||
| CiteScore （ 2026年6月最新版） |
| |||||||||||||||||||||||||||||||||||||
| 期刊简介 |
| |||||||||||||||||||||||||||||||||||||
| 期刊官方网站 | https://jitc.bmj.com/ | |||||||||||||||||||||||||||||||||||||
期刊投稿格式模板 VIP专享 |
| |||||||||||||||||||||||||||||||||||||
| 期刊投稿网址 | https://mc.manuscriptcentral.com/jitc | |||||||||||||||||||||||||||||||||||||
| 作者指南网址 | https://jitc.bmj.com/pages/authors | |||||||||||||||||||||||||||||||||||||
| 该期刊中国学者近期发文 - New | Targeting VEGF signaling and stromal remodeling enhances chemoimmunotherapy efficacy in esophageal cancer Author: Yu, Zhongjian; Li, Wenjia; Xu, Shiting; Xu, Meng; Lin, Qi; Liu, Lu; Zhang, Jiangyu; Zhong, Xi; Jin, Chuan; Zuo, Liu; Cai, Rui; Wang, Meng; Huang, Hongxin; Zhu, Xiongjie; Riaz, Muhammad; Suo, Shengbao; Zhou, Ming; Zheng, Yanfang Journal: JOURNAL FOR IMMUNOTHERAPY OF CANCER. 2026; Vol. 14, Issue 5, pp. -. DOI: 10.1136/jitc-2025-014249 Clinical outcomes and spatial transcriptomic profiles of CD19/20 CAR-T therapy in relapsed or refractory B-cell non-Hodgkin's lymphoma Author: Wang, Lixin; Fang, Chuling; Zheng, Yuanyuan; Xu, Yuanyuan; Huang, Wenfa; Zhao, Weiqiang; Wang, Yiran; Xia, Jianglong; Tan, Kun; Wang, Lei; Peng, Huixin; Guo, Xiao; Wang, Shuhong; Wang, Lijun; Liu, Lian; Qiao, Jingqiao; Meng, Xiangyu; He, Ziqian; Wen, Zonghua; Yu, Chuan; Mei, Junhui; Wang, Hongxin; Li, Yisheng; Yu, Li Journal: JOURNAL FOR IMMUNOTHERAPY OF CANCER. 2026; Vol. 14, Issue 5, pp. -. DOI: 10.1136/jitc-2026-015114 Targeting CD74 may mitigate immune-escape features and enhance BCMA CAR-T activity in preclinical models of relapsed/refractory multiple myeloma Author: Chen, Xinzhuo; Zhang, Jingjing; Chen, Hui; Huang, Renhua; Zhou, Xiaoxiao; Wang, Huiping; Xiao, Hao; Peng, Qian; Wu, Fan; Zhai, Zhimin; Wang, Zhitao Journal: JOURNAL FOR IMMUNOTHERAPY OF CANCER. 2026; Vol. 14, Issue 5, pp. -. DOI: 10.1136/jitc-2025-013255 First-in-human single-cell and TCR atlas reveals peripheral immune remodeling before and after irreversible electroporation in prostate cancer Author: Xiang, Jia-Cheng; Xia, Zhi-Yu; Sun, Jian-Xuan; Ye, Gui-Chen; Wang, Yuan; Yang, Jun; Wang, Shao-Gang; Xia, Qi-Dong Journal: JOURNAL FOR IMMUNOTHERAPY OF CANCER. 2026; Vol. 14, Issue 5, pp. -. DOI: 10.1136/jitc-2025-014288 | |||||||||||||||||||||||||||||||||||||
| 期刊语言要求 | 经LetPub语言功底雄厚的美籍native English speaker精心编辑的稿件，不仅能满足Journal for ImmunoTherapy of Cancer的语言要求，还能让Journal for ImmunoTherapy of Cancer编辑和审稿人得到更好的审稿体验，让稿件最大限度地被Journal for ImmunoTherapy of Cancer编辑和审稿人充分理解和公正评估。LetPub的专业SCI论文编辑服务（包括SCI论文英语润色，同行资深专家修改润色，SCI论文专业翻译，SCI论文格式排版，专业学术制图等）帮助作者准备稿件，已助力全球15万+作者顺利发表论文。部分发表范例可查看：服务好评 论文致谢（2篇） 。
提交文稿 | |||||||||||||||||||||||||||||||||||||
| 是否OA开放访问 | Yes | |||||||||||||||||||||||||||||||||||||
OA期刊相关信息 | 文章处理费：需要（ USD3180; ） 文章处理费豁免：查看说明 其他费用：没有 期刊主题关键词：tumour immunology、cancer immunotherapy、immunotherapy biomarkers 相关链接：Aims & ScopeAuthor InstructionsEditorial BoardAnonymous peer review | |||||||||||||||||||||||||||||||||||||
| 通讯方式 | BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND, WC1H 9JR | |||||||||||||||||||||||||||||||||||||
| 出版商 | BMJ PUBLISHING GROUP | |||||||||||||||||||||||||||||||||||||
| 涉及的研究方向 | Biochemistry, Genetics and Molecular Biology-Molecular Medicine | |||||||||||||||||||||||||||||||||||||
| 出版国家或地区 | UNITED STATES | |||||||||||||||||||||||||||||||||||||
| 出版语言 | English | |||||||||||||||||||||||||||||||||||||
| 出版周期 | ||||||||||||||||||||||||||||||||||||||
| 出版年份 | 2013 | |||||||||||||||||||||||||||||||||||||
| 年文章数 | 587点击查看年文章数趋势图 | |||||||||||||||||||||||||||||||||||||
| Gold OA文章占比 | 100.00% | |||||||||||||||||||||||||||||||||||||
| 研究类文章占比： 文章 ÷（文章 + 综述） | 95.06% | |||||||||||||||||||||||||||||||||||||
| 期刊分区表预警名单 | 2026年03月发布的新锐学术版：不在预警名单中 2025年03月发布的2025版：不在预警名单中 2024年02月发布的2024版：不在预警名单中 2023年01月发布的2023版：不在预警名单中 2021年12月发布的2021版：不在预警名单中 2020年12月发布的2020版：不在预警名单中 | |||||||||||||||||||||||||||||||||||||
  | ||||||||||||||||||||||||||||||||||||||
| 《新锐期刊分区表》 （ 2026年3月发布） | 点击查看期刊分区表趋势图
| |||||||||||||||||||||||||||||||||||||
| 期刊分区表 （ 2025年3月升级版） |
| |||||||||||||||||||||||||||||||||||||
| 期刊分区表 （ 2023年12月旧的升级版） |
| |||||||||||||||||||||||||||||||||||||
| SCI期刊收录coverage | Science Citation Index Expanded (SCIE) (2020年1月，原SCI撤销合并入SCIE，统称SCIE) Scopus (CiteScore) Directory of Open Access Journals (DOAJ) | |||||||||||||||||||||||||||||||||||||
| PubMed Central (PMC)链接 | http://www.ncbi.nlm.nih.gov/nlmcatalog?term=2051-1426%5BISSN%5D | |||||||||||||||||||||||||||||||||||||
| 平均审稿速度 | 网友分享经验： 18 Weeks | |||||||||||||||||||||||||||||||||||||
| 平均录用比例 | 网友分享经验： | |||||||||||||||||||||||||||||||||||||
| 版面费/APC文章处理费信息 | 文章处理费：需要（ USD3180; ） 文章处理费豁免：查看说明 其他费用：没有 LetPub提供文章处理费（APC）支持服务，可以用人民币支付版面费啦！ | |||||||||||||||||||||||||||||||||||||
| LetPub助力发表 | 经LetPub编辑的稿件平均录用比例是未经润色的稿件的1.5倍，平均审稿时间缩短40%。众多作者在使用LetPub的专业SCI论文编辑服务（包括SCI论文英语润色，同行资深专家修改润色，SCI论文专业翻译，SCI论文格式排版，专业学术制图等）后论文在Journal for ImmunoTherapy of Cancer顺利发表。
快看看作者怎么说吧：服务好评 论文致谢（2篇） 。 提交文稿 | |||||||||||||||||||||||||||||||||||||
| 期刊常用信息链接 |
| |||||||||||||||||||||||||||||||||||||
|
|
| |
| 中国学者近期发表的论文 | |
| 1. | Targeting VEGF signaling and stromal remodeling enhances chemoimmunotherapy efficacy in esophageal cancer Author: Yu, Zhongjian; Li, Wenjia; Xu, Shiting; Xu, Meng; Lin, Qi; Liu, Lu; Zhang, Jiangyu; Zhong, Xi; Jin, Chuan; Zuo, Liu; Cai, Rui; Wang, Meng; Huang, Hongxin; Zhu, Xiongjie; Riaz, Muhammad; Suo, Shengbao; Zhou, Ming; Zheng, Yanfang Journal: JOURNAL FOR IMMUNOTHERAPY OF CANCER. 2026; Vol. 14, Issue 5, pp. -. DOI: 10.1136/jitc-2025-014249 PubMed DOI |
| 2. | Clinical outcomes and spatial transcriptomic profiles of CD19/20 CAR-T therapy in relapsed or refractory B-cell non-Hodgkin's lymphoma Author: Wang, Lixin; Fang, Chuling; Zheng, Yuanyuan; Xu, Yuanyuan; Huang, Wenfa; Zhao, Weiqiang; Wang, Yiran; Xia, Jianglong; Tan, Kun; Wang, Lei; Peng, Huixin; Guo, Xiao; Wang, Shuhong; Wang, Lijun; Liu, Lian; Qiao, Jingqiao; Meng, Xiangyu; He, Ziqian; Wen, Zonghua; Yu, Chuan; Mei, Junhui; Wang, Hongxin; Li, Yisheng; Yu, Li Journal: JOURNAL FOR IMMUNOTHERAPY OF CANCER. 2026; Vol. 14, Issue 5, pp. -. DOI: 10.1136/jitc-2026-015114 PubMed DOI |
| 3. | Targeting CD74 may mitigate immune-escape features and enhance BCMA CAR-T activity in preclinical models of relapsed/refractory multiple myeloma Author: Chen, Xinzhuo; Zhang, Jingjing; Chen, Hui; Huang, Renhua; Zhou, Xiaoxiao; Wang, Huiping; Xiao, Hao; Peng, Qian; Wu, Fan; Zhai, Zhimin; Wang, Zhitao Journal: JOURNAL FOR IMMUNOTHERAPY OF CANCER. 2026; Vol. 14, Issue 5, pp. -. DOI: 10.1136/jitc-2025-013255 PubMed DOI |
| 4. | First-in-human single-cell and TCR atlas reveals peripheral immune remodeling before and after irreversible electroporation in prostate cancer Author: Xiang, Jia-Cheng; Xia, Zhi-Yu; Sun, Jian-Xuan; Ye, Gui-Chen; Wang, Yuan; Yang, Jun; Wang, Shao-Gang; Xia, Qi-Dong Journal: JOURNAL FOR IMMUNOTHERAPY OF CANCER. 2026; Vol. 14, Issue 5, pp. -. DOI: 10.1136/jitc-2025-014288 PubMed DOI |
| 5. | CXCL16-driven CD4+ T cells orchestrate immunosurveillance against MHC-I-deficient hepatocellular tumors Author: Zhou, Yunyi; Chen, Ping; Wang, Zhixue; Gui, Liming; Zheng, Zhengheng; Gao, Wei-Qiang; Ma, Bin Journal: JOURNAL FOR IMMUNOTHERAPY OF CANCER. 2026; Vol. 14, Issue 5, pp. -. DOI: 10.1136/jitc-2025-012347 PubMed DOI |
| 6. | Simplified perioperative serplulimab and chemotherapy for resectable squamous NSCLC: a phase II trial with biomarker analysis Author: Fu, Fangqiu; Wu, Haoxuan; Deng, Chaoqiang; Chen, Haiqing; Huang, Qingyuan; Yuan, Chongze; Ding, Xusheng; Ye, Ting; Zhou, Yaodong; Chen, Sufeng; Sun, Yihua; Zhang, Yawei; Xiang, Jiaqing; Wang, Shengping; Li, Yuan; Li, Bing; Lu, Yi; Zhang, Yang; Hu, Hong; Chen, Haiquan Journal: JOURNAL FOR IMMUNOTHERAPY OF CANCER. 2026; Vol. 14, Issue 5, pp. -. DOI: 10.1136/jitc-2025-014437 PubMed DOI |
| 7. | Sensory neuron-derived CCL5 orchestrates an immunosuppressive niche via regulatory T cells to fuel head and neck tumor progression Author: Wu, Kailiu; Zhang, Zhen; Qin, Xing; Feng, Guanying; Li, Huasheng; Guo, Ruiyu; Hu, Yuhua; Ji, Yikang; Wang, Yang; Yan, Ming; Zhang, Chenping Journal: JOURNAL FOR IMMUNOTHERAPY OF CANCER. 2026; Vol. 14, Issue 5, pp. -. DOI: 10.1136/jitc-2025-013958 PubMed DOI |
| 8. | VISTA neutralization by immunization reprograms immunosuppression and augments vaccine efficacy in renal carcinoma Author: Wang, Jiawei; Wang, Zhenzhen; Zhao, Wanting; Chen, Haomin; Lu, Bowen; Shao, Yingxiang; Zheng, Yanyan; Liu, Shanshan; Wang, Meng; Fang, Lin; Li, Huizhong; Neeli, Praveen; Tian, Hui; Wang, Gang; Chai, Dafei Journal: JOURNAL FOR IMMUNOTHERAPY OF CANCER. 2026; Vol. 14, Issue 5, pp. -. DOI: 10.1136/jitc-2026-015052 PubMed DOI |
| 9. | LGALS9 blockade augments vaccine-induced immune responses against prostate cancer Author: Lu, Bowen; Liu, Ning; Zhao, Wanting; Chen, Haomin; Shao, Yingxiang; Lu, Haosen; Liu, Shanshan; Yang, Jie; Zheng, Yanyan; Ding, Jiage; Chai, Dafei; Mao, Lijun Journal: JOURNAL FOR IMMUNOTHERAPY OF CANCER. 2026; Vol. 14, Issue 5, pp. -. DOI: 10.1136/jitc-2025-014141 PubMed DOI |
| 10. | Patient-derived organotypic tumor spheroids as a functional platform for predicting immunotherapeutic responses and guiding precision treatment for hepatocellular carcinoma Author: Song, Fei; Lu, Yi-Jun; Sun, Hai-Xiang; Cheng, Jian-Wen; Li, Wen-Zhen; Liu, Zhenhao; Li, Rui-Zhe; Wang, Peng-Xiang; Zheng, Wen-Jing; Zhong, Yu-Chen; Xu, Yang; Xu, Jie; Wang, Yu; Bai, Su-Yan; Xie, Lu; Man, Kwan; Fan, Jia; Zhou, Jian; Chen, Zhong; Yang, Xin-Rong Journal: JOURNAL FOR IMMUNOTHERAPY OF CANCER. 2026; Vol. 14, Issue 5, pp. -. DOI: 10.1136/jitc-2025-014555 PubMed DOI |
|
|
  | ||||||||||||||||
|
投稿状态统计： 我要评分： | ||||||||||||||||
| 投稿前担心稿件结构或语言不够规范？试试稿件自查工具，一键检测 >> | ||||||||||||||||
|
||||||||||||||||
同领域作者分享投稿经验：共382条 |
||||||||||||||||
|
|
联系我们 | 站点地图 | 友情链接 | 授权代理商 | 加入我们
© 2010-2026 中国: LetPub上海 网站备案号：沪ICP备10217908号-1 
沪公网安备号：31010402006960 （网站）31010405000484 （蝌蝌APP）
增值电信业务经营许可证：沪B2-20211595 网络文化经营许可证：沪网文[2023]2004-152号
礼翰商务信息咨询（上海）有限公司 办公地址：上海市徐汇区漕溪北路88号圣爱大厦1803室
安全保密
投稿信 (Cover Letter) 模板
